MAPT and Cognitive impairment: Numerous previous studies have shown PS cDKO exhibits Alzheimer’s like neurodegenerative symptoms, including cognitive deficits, shrinkage of the cortex, neuroinflammation, and tau hyperphosphorylation in the late stage, despite the decreased Aβ content [8, 60, 81, 89].